Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, August 19 at 2:00 PM EDT

Register Free →

FY24 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science Award Notice

Active
FDABAA-24-00123_AwardFederal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The FY24 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science resulted in the awarding of 22 contracts during the fiscal year 2024. This initiative, managed by the FDA Office of Acquisitions and Grants Services under the Department of Health and Human Services, specifically targets projects related to regulatory science research and development under the NAICS code 541714. The contracts are part of a special notice solicitation identified as FDABAA-24-00123_Award, with the announcement posted on October 24, 2024. The contracts are being administered through the FDA Office of Acquisitions and Grants Services located in Rockville, MD, while the primary place of performance is Silver Spring, MD. Contact for further information is Ian Weiss, reachable via email or phone. This broad agency announcement supports FDA’s commitment to advancing regulatory science by funding innovative research projects that contribute directly to the agency’s mission of protecting public health.

General Info

FDA awarded 22 FY24 contracts for regulatory science research under NAICS 541714, managed in MD.

Agency

Department Of Health And Human Services → FDA Office Of Acquisitions And Grants ServicesView Agency

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)View NAICS

Place of Performance

Silver Spring, MD, 20993, USA

Set-Aside

NONE

Documents

(1)

BAA_AwardedFY24.pdf

PDF

AI Contract Breakdown

Uniform Contract Format

What is UCF?

Uniform Contract Format (UCF) uses AI to break down any contract into standardized sections—scope, pricing, deliverables, and evaluation criteria.

Timeline

1 update
Posted

special-notice

Amendment 1

Contract was updated

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → FDA Office Of Acquisitions And Grants Services
Contacts1 person available
OfficeRockville, MD, 20857, USA
Organization / Agency
Department Of Health And Human Services → FDA Office Of Acquisitions And Grants Services
View Agency Profile
Office AddressRockville, MD, 20857, USA

Full Description

Show more
Please see attached Spreadsheet for all contracts awarded in this oppertunity. A total of 22 Contracts were awarded in FY24 from this BAA Announcement.

Similar Contracts

Same NAICS industry code

NAICS: 541714
New
Federal
Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA)
Solicitation # W911SR-26-R-HEAL
The Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA) is a continuous, open solicitation designed to establish a dynamic, pre-qualified network of partners to accelerate the development and fielding of next-generation medical defenses against CBRN threats. Operated by the Capability Program Executive for CBRN Defense (CPE CBRND) under the Department of Defense, this agreement functions as an Indefinite-Delivery Indefinite-Quantity (IDIQ)-like vehicle authorized under 10 U.S.C. §§4021, 4022, and 4023, exempting it from the Competition in Contracting Act of 1984. The program seeks innovative, threat-agnostic host-directed therapeutics that enhance physiological resilience by targeting critical systems such as neurological function, respiratory stability, immune response, hematologic and vascular integrity, and cellular stress and repair pathways. Complementary to this, the government also seeks broad-spectrum therapeutic candidates that can directly neutralize CBRN agents, with emphasis on agents possessing environmental stability, non-cold-chain storage capability, and simplified administration routes like oral, intranasal, or autoinjector formats suitable for immediate use in austere, far-forward operational environments. Interested parties, including MCM developers at any stage from Phase I through FDA licensure and supporting organizations such as CROs, CDMOs, and regulatory experts, must submit a white paper of no more than five pages detailing product mechanisms, efficacy data from validated animal models, regulatory status including IND history and clinical trial results, manufacturing capacity and scale-up plans, and company experience. Collaboration is mandatory, with applicants required to state willingness to team or partner within the PBA ecosystem. Participation requires SAM registration, and all award decisions are based on technical merit and strategic alignment with the program’s mission to build a layered, resilient, and sustainable medical defense portfolio, without fixed deadlines or competitive bidding. The agreement supports the development of dual-use medical solutions with potential applications in civilian critical care, emphasizing ruggedized formulations, clear labeling, durable packaging, and long-term stability to ensure readiness in the most challenging operational conditions. Technical and administrative inquiries should be directed to Hunter Robinson or Alexander Mayatte at the Aberdeen Proving Ground, Maryland office.
W6QK Acc-Apg

POSTED

1 day ago

DEADLINE

N/A
View Details
NAICS: 541714
New
Federal
Validation and Optimization of ONE-STEP Tagging in Human induced Pluripotent Stem Cells
Solicitation # NIH-NOI-PCA-NIA-01590
The National Institute on Aging (NIA), under the National Institutes of Health (NIH) and Department of Health and Human Services (HHS), has issued a Notice of Intent to Sole Source for the validation and optimization of ONE-STEP tagging in human induced pluripotent stem cells (iPSCs). This acquisition aims to support the iPSC Neurodegenerative Disease Initiative (iNDI) and the Center of Alzheimer’s Disease and Related Dementias (CARD) by generating functionally engineered iPSC lines for research into Alzheimer’s disease and related dementias. The project involves high-activity guide identification, Bxb1 mRNA and cargo plasmid delivery optimization, and the generation of ADRD variant, MAPT 4R, and wild-type process-control clones. All deliverables must be repository-ready, meeting strict quality control standards including long-read sequencing, karyotype analysis, and SNP arrays to ensure scientific continuity and data integrity. The government intends to award this contract to The Jackson Laboratory, citing them as the only responsible source capable of meeting the requirements under FAR 6.302-1 and FAR 13.501(a). This determination is based on the laboratory's unique continuity with the existing iNDI program, established workflows for specific background lines, and proven success in large-scale CRISPR/Cas9 engineering. The total estimated contract value is 3,353,115.00 dollars, covering a base year from September 1, 2026, to August 31, 2027, and an option year extending to August 31, 2028. While this is a sole-source intent, the government will consider capability statements from other sources submitted by August 21, 2026, to determine if adequate competition exists.
National Institutes Of Health Olao

POSTED

1 day ago

DEADLINE

in 2 days
View Details

More opportunities from Department Of Health And Human Services → FDA Office Of Acquisitions And Grants Services

Same awarding agency